SUZ12 and neurofibroma: Although our genome-wide CRISPRi screens in NF1-mutant, NF2-intact, PRC2-intact NF95.11b neurofibroma cells did not identify sgRNAs targeting SUZ12, EED, or other core PRC2 components as drivers of selumetinib resistance in vitro, the time course of epigenetic cellular de-differentiation may not be compatible with the time course of in vitro genome-wide screens.